The FDA has issued a 510(k) clearance for a new internal fixation system for Charcot foot.
FDA Clears New Treatment for Charcot Foot
1 min read Premium comments
#orthofixSecondary#diabetes#charcotfoot
The system, named the G-Beam™ Fusion Beaming System, is manufactured by Orthofix International N.V., a global medical device company focused on musculoskeletal healing products and value-added services.
According to the press release, “Designed primarily for the treatment of Charcot foot, a debilitating condition where the bones in the foot weaken and collapse, the G-Beam devices can be implanted in the medial and lateral columns of the foot to provide alignment, stabilization and fixation.”
“Charcot foot can occur in people who have severe neuropathy (the loss of protective sensation in the limb) or nerve damage which is a common diabetic foot complication.”
“In my practice I often see patients whose uncontrolled diabetes has led to the development of Charcot foot, an extremely disabling condition that if left untreated, can lead to amputation,” said William Grant, M.D., a podiatric surgeon from Virginia Beach, Virginia, who designed the G-Beam system. “Using the G-Beam system allows us to anatomically realign the foot; enabling the bones to heal so these patients can return to a more normal independent lifestyle.”
“The World Health Organization estimates that more than 422 million people suffer from diabetes and that the number will more than double in the next 20 years.”
“When the use of internal fixation is called for, the G-Beam system is designed to fuse the medial and/or lateral columns, as well as bones in the hindfoot, in order to restore a stable foot that may ultimately reduce the probability of an amputation. The system comes with single-use, sterile-packed implants and a compact instrumentation tray.”
Davide Bianchi, president of the Extremity Fixation business unit, said, “The G-Beam Fusion Beaming System is the next step in working towards our objective of becoming a recognized premium solution provider in the Charcot and Diabetic foot market segments This system will allow us to establish ourselves in the internal fixation segment of Charcot treatment options.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.